Innate Immunity in Allergic Asthma

Description

The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

Conditions

Asthma

Study Overview

Study Details

Study overview

The purpose of this study is to determine whether a potential type 2 signature, obtained through stimulation of cell lines with various allergens in vitro, correlates with an allergic or asthmatic disease state ex vivo. This type 2 signature will be multi-hierarchical in nature and will be comprised cell surface receptor expression, pathway activation, and gene upregulation.

Innate Immunity in Allergic Asthma

Innate Immunity in Allergic Asthma

Condition
Asthma
Intervention / Treatment

-

Contacts and Locations

Orlando

University of Central Florida, Orlando, Florida, United States, 32816

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • * Participants must be at least 18 years of age
  • * no history of allergic disease (healthy controls), have clinically diagnosed allergies, or have clinically diagnosed asthma.
  • * Pregnant women and prisoners will be excluded from the study.
  • * Individuals currently suffering from any acute infections and those known to suffer from light-headedness will be excluded.

Ages Eligible for Study

18 Years to

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

Yes

Collaborators and Investigators

University of Central Florida,

Justine T Tigno-Aranjuez, PhD, PRINCIPAL_INVESTIGATOR, University of Central Florida

Study Record Dates

2025-06